BSE Live
Mar 20, 16:01Prev. Close
113.70
Open Price
113.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:59Prev. Close
114.36
Open Price
116.08
Bid Price (Qty.)
118.22 (2225)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Kopran (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 35.79 | 44.52 | 36.92 | 16.16 | 32.71 | |
| Net CashFlow From Operating Activities | 23.30 | 34.96 | 16.87 | -37.81 | 48.77 | |
| Net Cash Used In Investing Activities | -15.41 | -6.27 | 10.05 | -100.26 | -8.51 | |
| Net Cash Used From Financing Activities | 5.64 | -24.08 | -26.13 | 138.00 | -40.14 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 13.53 | 4.61 | 0.79 | -0.07 | 0.12 | |
| Cash And Cash Equivalents Begin of Year | 5.65 | 1.04 | 0.25 | 0.32 | 0.21 | |
| Cash And Cash Equivalents End Of Year | 19.18 | 5.65 | 1.04 | 0.25 | 0.32 |
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth